N/A N=104 Randomized Single-blind Supportive Care

Improvisational Movement for People With Memory Loss and Their Caregivers

Alzheimer's Disease (Incl Subtypes) · Dementia · Mild Cognitive Impairment

Bottom Line

View on ClinicalTrials.gov: NCT03333837 ↗

Enrolled (actual)

104

Serious AEs

11.1%

Results posted

Jul 2022

Primary outcome: Primary: Quality of Life in Alzheimer's Disease (QOL-AD)--Participants With Dementia (PWD) — 35.42; 38.10; 35.56; 36.12 score on a scale

Study Design & Population

Study type: Interventional
Phase: N/A
Interventions: Dance Group (Behavioral); Non-Group Dance (Behavioral); Social Group (Behavioral); No Contact (Behavioral)
Age: Adult, Older Adult · 60+ yrs
Sex: All
Sponsor: Wake Forest University Health Sciences
Primary completion: May 2021

Outcome Measures

Outcome	Result	p-value
PRIMARY Quality of Life in Alzheimer's Disease (QOL-AD)--Participants With Dementia (PWD)	35.42; 38.10; 35.56; 36.12	—
PRIMARY QOL-AD--PWD	35.23; 40.0; 36.68; 35.96	—
SECONDARY Community Structure--PWD	.74; .73; .75; .75	—
SECONDARY Community Structure--PWD	.74; .73; .75; .75	—
SECONDARY Global Efficiency (eGlob)--PWD	.19; .18; .19; .19	—
SECONDARY Global Efficiency (eGlob)--PWD	.19; .18; .19; .19	—
SECONDARY Local Efficiency (eLoc)--PWD	.58; .58; .59; .58	—
SECONDARY Local Efficiency (eLoc)--PWD	.58; .58; .59; .58	—
SECONDARY Path Length--PWD	5.30; 5.61; 5.36; 5.54	—
SECONDARY Path Length--PWD	5.30; 5.61; 5.36; 5.54	—
SECONDARY Fullerton Advanced Balance Scale (Overall Balance) PWD	23.41; 29.95; 24.27; 26.78	—
SECONDARY Fullerton Advanced Balance Scale (Overall Balance) PWD	23.41; 29.95; 24.27; 26.78	—
SECONDARY Falls Efficacy Scale - International (FES) PWD	27.23; 21.73; 25.36; 28.09	—
SECONDARY Falls Efficacy Scale - International (FES) PWD	27.23; 21.73; 25.36; 28.09	—
SECONDARY Neuropsychiatric Inventory Questionnaire (NPI-Q)	6.83; 5.44; 6.85; 7.72	—
SECONDARY NPI-Q	6.38; 5.22; 5.63; 8.39	—
SECONDARY Geriatric Depression Scale	2.27; 1.32; 1.68; 2.74	—
SECONDARY Geriatric Depression Scale	2.27; 1.32; 1.68; 2.74	—
SECONDARY Geriatric Anxiety Scale	3.64; 2.23; 3.64; 4.0	—
SECONDARY Geriatric Anxiety Scale	3.64; 2.23; 3.64; 4.0	—
SECONDARY Apathy Evaluation Scale--PWD	19.32; 19.0; 18.68; 22.87	—
SECONDARY Apathy Evaluation Scale--PWD	19.32; 19.0; 18.68; 22.87	—
SECONDARY Expanded Short Physical Performance Battery (eSPPB)	1.62; 1.98; 1.66; 1.88	—
SECONDARY Expanded Short Physical Performance Battery (eSPPB)	1.62; 1.98; 1.66; 1.88	—
SECONDARY Postural Sway--PWD	0.41; 0.38; 0.41; 0.52	—
SECONDARY Postural Sway--PWD	0.41; 0.38; 0.41; 0.52	—
SECONDARY Gait Speed--PWD	5.51; 4.79; 5.12; 4.77	—
SECONDARY Gait Speed--PWD	5.51; 4.79; 5.12; 4.77	—
SECONDARY Gait Variability--PWD	4.46; 2.71; 3.45; 4.06	—
SECONDARY Gait Variability--PWD	4.46; 2.71; 3.45; 4.06	—

Summary

Dementia is a progressive decline in cognition that impairs a person's ability to perform activities of daily living. Changes in mood, gait, and balance are prominent secondary symptoms of Alzheimer's dementia that can dramatically decrease quality of life for the person with dementia and increase caregiver burden. The overall aim of this study is to determine the independent and combined effects of dance movement and social engagement on quality of life in people with early-stage dementia, and test the neural mechanisms of these effects.

Eligibility Criteria

Inclusion Criteria

Age 60-85 years

Adjudicated as having mild cognitive impairment or early-stage dementia of Alzheimer's, vascular, or mixed Alzheimer's/vascular type

MRI compatible

English speaking

Have study partner who is around the person with dementia approximately 10 hours/week and is willing to be an active study partner.

Able to attend bi-weekly intervention classes or come to study visits for no-contact control.

Not enrolled in another interventional study for at least 3 months prior to beginning this study.

Exclusion Criteria

Untreated depression

Other causes of dementia (for example, frontotemporal, early onset, Lewy body or Parkinsonian dementia)

Current cancer treatment or other major medical problems that might independently affect cognition or movement

Other neurological disorders (e.g., Parkinson disease, multiple sclerosis)

Taking medication that could negatively influence safety during intervention

Planned extensive travel during the study period

Any reason for which the study doctor or personal physician feels the intervention is contraindicated for the participant

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03333837). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.